| Identification | Back Directory | [Name]
JNJ 4796) | [CAS]
2241664-16-2 | [Synonyms]
JNJ 4796)
JNJ4796
(JNJ-4796
(R)-N-(2-(2-(4-((2-methyl-2H-tetrazol-5-yl)(phenyl)methyl)piperazine-1-carbonyl)pyridin-4-yl)benzo[d]oxazol-5-yl)acetamide
Acetamide, N-[2-[2-[[4-[(R)-(2-methyl-2H-tetrazol-5-yl)phenylmethyl]-1-piperazinyl]carbonyl]-4-pyridinyl]-5-benzoxazolyl]- | [Molecular Formula]
C28H27N9O3 | [MDL Number]
MFCD32062806 | [MOL File]
2241664-16-2.mol | [Molecular Weight]
537.58 |
| Chemical Properties | Back Directory | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (186.02 mM; Need ultrasonic) | [form ]
Solid | [pka]
13.03±0.43(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1]. | [in vivo]
Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved[1].
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD90), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1]. | Animal Model: | Female BALB/cAnNCrl mice intranasally infected with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34 dissolved in sterile phosphate buffered saline (D-PBS)[1] | | Dosage: | 50 and 10 mg/kg. | | Administration: | Oral twice daily for 7 days. | | Result: | Resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897. |
| [storage]
Store at -20°C | [References]
[1] van Dongen MJP, et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019 Mar 8;363(6431). DOI:10.1126/science.aar6221 |
|
|